Ryan T. Fischer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ryan T. Fischer has a total of 348 co-authors. Here are the top co-authors by number of shared publications:
- Richard J. Hendrickson
Department of Pediatric Surgery, Children’s Mercy Kansas City, Missouri, USA
6 shared publications - Heth R. Turnquist
Department of Surgery, University of Pittsburgh, Pittsburgh, PA, USA
4 shared publications James F. Daniel
Division of Gastroenterology Children's Mercy Hospital Kansas City Missouri USA
4 shared publicationsAlan N. Langnas
Department of Transplant Surgery University of Nebraska Medical Center Omaha NE USA
3 shared publicationsRuben E. Quiros‐Tejeira
45 Department of Pediatrics, Children's Hospital & Medical Center and University of Nebraska Medical Center, Omaha, Nebraska, USA
3 shared publicationsWalter S. Andrews
Department of Surgery, Children's Mercy Kansas City, Kansas City, Missouri, USA
3 shared publications
Latest Publications
- 14 October 2026
- Published by Wolters Kluwer Health in Liver Transplantation
Long-term graft and patient survival of patients with portal vein stenosis after pediatric liver transplantation: Results from the multicenter multinational PORTAL registry
Pediatric liver transplantation (pLT) has become a standard treatment, but it is still burdened by complications such as portal vein stenosis (PVS). PVS can result in compromised graft function and portal hypertension if left untreated. We aimed to assess long-term patient and graft survival after PVS diagnosis following pLT. Our study analyzed data from the Portal Vein Obstruction Revascularisation Therapy After Liver Transplantation (PORTAL) registry, which contains retrospective data from 21 centers across 18 countries, over a 20-year period. Graft and patient survival rates were determined after PVS diagnosis. This study included 239 patients (53% female; median age at pLT 1.1 y) diagnosed with PVS. The median age at diagnosis was 2.7 years. The overall 10-year graft survival was 90%, and the 10-year patient survival was 96%. One-year graft and patient survival were lowest in patients with PVS diagnosed ≤7 days after pLT (80% and 92%, respectively). Initial treatment strategies comprised mostly endovascular procedures (87%), followed by conservative (11%) and surgical treatment (3%). Patient outcomes did not differ between these treatment groups. Within the endovascular group, graft survival in patients treated with stent (n=26) was significantly lower compared with those with percutaneous transluminal angioplasty (n=181) (88% vs. 98%, respectively, p =0.01). Our findings indicate excellent graft and patient survival after PVS diagnosis and its treatment. Further research is needed to determine the safety and efficacy of optimal management strategies, especially in early-onset PVS.
- 14 October 2026
- Published by Wolters Kluwer Health in Liver Transplantation
Long-term graft and patient survival of patients with portal vein stenosis after pediatric liver transplantation: Results from the multicenter multinational PORTAL registry
Pediatric liver transplantation (pLT) has become a standard treatment, but it is still burdened by complications such as portal vein stenosis (PVS). PVS can result in compromised graft function and portal hypertension if left untreated. We aimed to assess long-term patient and graft survival after PVS diagnosis following pLT. Our study analyzed data from the Portal Vein Obstruction Revascularisation Therapy After Liver Transplantation (PORTAL) registry, which contains retrospective data from 21 centers across 18 countries, over a 20-year period. Graft and patient survival rates were determined after PVS diagnosis. This study included 239 patients (53% female; median age at pLT 1.1 y) diagnosed with PVS. The median age at diagnosis was 2.7 years. The overall 10-year graft survival was 90%, and the 10-year patient survival was 96%. One-year graft and patient survival were lowest in patients with PVS diagnosed ≤7 days after pLT (80% and 92%, respectively). Initial treatment strategies comprised mostly endovascular procedures (87%), followed by conservative (11%) and surgical treatment (3%). Patient outcomes did not differ between these treatment groups. Within the endovascular group, graft survival in patients treated with stent (n=26) was significantly lower compared with those with percutaneous transluminal angioplasty (n=181) (88% vs. 98%, respectively, p =0.01). Our findings indicate excellent graft and patient survival after PVS diagnosis and its treatment. Further research is needed to determine the safety and efficacy of optimal management strategies, especially in early-onset PVS.
- Open Access
- 31 March 2026
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 10 (4)
CD8 TRM-like T cells expressing perforin and IFN-γ define a pediatric activated T-cell acute liver failure endotype
Background: Activated T-cell pediatric acute liver failure (TC-PALF) is the most common cause of non-acetaminophen PALF, with poor transplant-free survival. Livers in TC-PALF are infiltrated by effector cytotoxic T lymphocytes with markers of tissue-resident memory function (CD8 Trm) and an interferon gamma (IFNγ) transcriptional signature. The PALF-Immune Response Network (PALF-IRN) and the prospective TReatment for ImmUne-Mediated PathopHysiology (TRIUMPH) clinical trial (NCT04862221) aim to characterize the TC-PALF immune pathology and utility of T-cell directed therapy to improve transplant-free survival. Methods: TRIUMPH patients with TC-PALF were compared with healthy children and disease controls utilizing multiparameter flow cytometry and 3′ single-cell RNA sequencing from peripheral blood mononuclear cells. TC-PALF patient serum was compared with healthy children and those with PALF from other causes, utilizing the Olink Inflammation I 384 protein assay. Results: Two distinct endotypes of TC-PALF were identified, which differed in flow cytometry CD8+ Perforin1 (Prf) expression and liver biopsy staining of Prf. TC-PALF patients with high CD8+ Prf (TC-PALF High Prf) had monocytosis, with a unique circulating CD8 IFNγ+ Trm-like population and IFNγ-responsive CD14/CD16 monocyte ligand–receptor interaction. TC-PALF patients with normal CD8+ Prf expression had hypergammaglobulinemia, an increase in class-switched B-cells, and a decrease in serum inflammatory proteins associated with myeloid activation. Conclusions: TC-PALF high Prf patients have a unique circulating CD8+ IFNγ+ Trm-like population accompanied by monocyte proliferation and activation. Further understanding of the role of IFNγ in TC-PALF High Prf may provide a therapeutic target for this endotype to improve transplant-free survival. Export
- 31 March 2026
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 10 (4)
Open AccessCD8 TRM-like T cells expressing perforin and IFN-γ define a pediatric activated T-cell acute liver failure endotype
Background: Activated T-cell pediatric acute liver failure (TC-PALF) is the most common cause of non-acetaminophen PALF, with poor transplant-free survival. Livers in TC-PALF are infiltrated by effector cytotoxic T lymphocytes with markers of tissue-resident memory function (CD8 Trm) and an interferon gamma (IFNγ) transcriptional signature. The PALF-Immune Response Network (PALF-IRN) and the prospective TReatment for ImmUne-Mediated PathopHysiology (TRIUMPH) clinical trial (NCT04862221) aim to characterize the TC-PALF immune pathology and utility of T-cell directed therapy to improve transplant-free survival. Methods: TRIUMPH patients with TC-PALF were compared with healthy children and disease controls utilizing multiparameter flow cytometry and 3′ single-cell RNA sequencing from peripheral blood mononuclear cells. TC-PALF patient serum was compared with healthy children and those with PALF from other causes, utilizing the Olink Inflammation I 384 protein assay. Results: Two distinct endotypes of TC-PALF were identified, which differed in flow cytometry CD8+ Perforin1 (Prf) expression and liver biopsy staining of Prf. TC-PALF patients with high CD8+ Prf (TC-PALF High Prf) had monocytosis, with a unique circulating CD8 IFNγ+ Trm-like population and IFNγ-responsive CD14/CD16 monocyte ligand–receptor interaction. TC-PALF patients with normal CD8+ Prf expression had hypergammaglobulinemia, an increase in class-switched B-cells, and a decrease in serum inflammatory proteins associated with myeloid activation. Conclusions: TC-PALF high Prf patients have a unique circulating CD8+ IFNγ+ Trm-like population accompanied by monocyte proliferation and activation. Further understanding of the role of IFNγ in TC-PALF High Prf may provide a therapeutic target for this endotype to improve transplant-free survival. Export
- 29 January 2026
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 82 (4) , 949-958
Baseline analysis of patient reported outcomes in the progressive familial intrahepatic cholestasis patient registry
Objectives: Progressive familial intrahepatic cholestasis (PFIC) is an overarching term for rare monogenic defects that result in cholestatic liver disease. Larger consortia‐based registries have begun to address the challenges of PFIC as a rare disease with variable phenotype, but patient‐reported outcomes (PROs) have not been extensively described. Here, we report baseline analysis from the PFIC network patient registry (PNPR), an effort to report outcome measures identified as meaningful and impactful to those living with the disease. Methods: The PNPR is a prospective, international, voluntary patient registry collecting longitudinal PROs relevant to PFIC and its complications, including diagnosis, symptoms, surgeries, medications as well as validated measures related to itch, sleep, and general health (patient‐reported outcomes measurement information system [PROMIS] measures), disease impact on family quality of life (QoL), and financial burden of the disease. Results: Baseline data from 161 international patients were included. Registrants included patients affected by several subtypes and benign recurrent intrahepatic cholestasis, and 19 participants with an unknown or missing diagnosis. Pruritus is an important contributor to morbidity with severity of itch positively correlating with sleep disturbance and sleep impairment and negatively correlating with family QoL and overall health. The financial burden of disease was reflected by higher out‐of‐pocket medical costs and more reported challenges arranging medical care compared to the general US population. Conclusion: The PNPR fills a previously identified gap in PFIC research—the lack of PROs—and reveals the negative impact of disease and pruritus on patient and family function, QoL indicators, finances, and measures of general health.
- 29 January 2026
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 82 (4) , 949-958
Baseline analysis of patient reported outcomes in the progressive familial intrahepatic cholestasis patient registry
Objectives: Progressive familial intrahepatic cholestasis (PFIC) is an overarching term for rare monogenic defects that result in cholestatic liver disease. Larger consortia‐based registries have begun to address the challenges of PFIC as a rare disease with variable phenotype, but patient‐reported outcomes (PROs) have not been extensively described. Here, we report baseline analysis from the PFIC network patient registry (PNPR), an effort to report outcome measures identified as meaningful and impactful to those living with the disease. Methods: The PNPR is a prospective, international, voluntary patient registry collecting longitudinal PROs relevant to PFIC and its complications, including diagnosis, symptoms, surgeries, medications as well as validated measures related to itch, sleep, and general health (patient‐reported outcomes measurement information system [PROMIS] measures), disease impact on family quality of life (QoL), and financial burden of the disease. Results: Baseline data from 161 international patients were included. Registrants included patients affected by several subtypes and benign recurrent intrahepatic cholestasis, and 19 participants with an unknown or missing diagnosis. Pruritus is an important contributor to morbidity with severity of itch positively correlating with sleep disturbance and sleep impairment and negatively correlating with family QoL and overall health. The financial burden of disease was reflected by higher out‐of‐pocket medical costs and more reported challenges arranging medical care compared to the general US population. Conclusion: The PNPR fills a previously identified gap in PFIC research—the lack of PROs—and reveals the negative impact of disease and pruritus on patient and family function, QoL indicators, finances, and measures of general health.
- 12 August 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (12) , 2499-2507
Addressing vaccination coverage among pediatric solid organ transplant candidates and recipients in the post-coronavirus disease 2019 pandemic period of increased vaccine hesitancy
- 12 August 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (12) , 2499-2507
Addressing vaccination coverage among pediatric solid organ transplant candidates and recipients in the post-coronavirus disease 2019 pandemic period of increased vaccine hesitancy
- Open Access
- 24 May 2025
- Published by Taylor & Francis in Future Rare Diseases
- Vol. 5 (1)
The effects of odevixibat in people with Alagille syndrome: a plain language summary
- 24 May 2025
- Published by Taylor & Francis in Future Rare Diseases
- Vol. 5 (1)
Open AccessThe effects of odevixibat in people with Alagille syndrome: a plain language summary
- 18 December 2023
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 30 (4) , 343-344
Looking for literal improvement in liver transplant outcomes
An abstract is unavailable. This article is available as a PDF only.
- 18 December 2023
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 30 (4) , 343-344
Looking for literal improvement in liver transplant outcomes
An abstract is unavailable. This article is available as a PDF only.
- 7 August 2023
- Published by Wiley in Pediatric Transplantation
- Vol. 28 (1) , e14516
Hepatic artery thrombosis and use of anticoagulants and antiplatelet agents in pediatric liver transplantation
Background: Hepatic artery thrombosis (HAT) is a reported complication of 5%–10% of pediatric liver transplantations, rates 3–4 times that seen in adults. Early HAT (seen within 14 days after transplant) can lead to severe allograft damage and possible urgent re‐transplantation. In this report, we present our analysis of HAT in pediatric liver transplant from a national clinical database and examine the association of HAT with anticoagulant or antiplatelet medication administered in the post‐operative period.Methods: Data were obtained from the Pediatric Health Information System database maintained by the Children's Hospital Association. For each liver transplant recipient identified in a 10‐year period, diagnosis, demographic, and medication data were collected and analyzed.Results: Our findings showed an average rate of HAT of 6.3% across 31 centers. Anticoagulant and antiplatelet medication strategies varied distinctly among and even within centers, likely due to the fact there are no consensus guidelines. Notably, in centers with similar medication usage, HAT rates continue to vary. At the patient level, use of aspirin within the first 72 h of transplantation was associated with a decreased risk of HAT, consistent with other reports in the literature.Conclusion: We suggest that concerted efforts to standardize anticoagulation approaches in pediatric liver transplant may be of benefit in the prevention of HAT. A prospective multi‐institutional study of regimen—possibly including aspirin—following transplantation could have significant value.
- 7 August 2023
- Published by Wiley in Pediatric Transplantation
- Vol. 28 (1) , e14516
Hepatic artery thrombosis and use of anticoagulants and antiplatelet agents in pediatric liver transplantation
Background: Hepatic artery thrombosis (HAT) is a reported complication of 5%–10% of pediatric liver transplantations, rates 3–4 times that seen in adults. Early HAT (seen within 14 days after transplant) can lead to severe allograft damage and possible urgent re‐transplantation. In this report, we present our analysis of HAT in pediatric liver transplant from a national clinical database and examine the association of HAT with anticoagulant or antiplatelet medication administered in the post‐operative period.Methods: Data were obtained from the Pediatric Health Information System database maintained by the Children's Hospital Association. For each liver transplant recipient identified in a 10‐year period, diagnosis, demographic, and medication data were collected and analyzed.Results: Our findings showed an average rate of HAT of 6.3% across 31 centers. Anticoagulant and antiplatelet medication strategies varied distinctly among and even within centers, likely due to the fact there are no consensus guidelines. Notably, in centers with similar medication usage, HAT rates continue to vary. At the patient level, use of aspirin within the first 72 h of transplantation was associated with a decreased risk of HAT, consistent with other reports in the literature.Conclusion: We suggest that concerted efforts to standardize anticoagulation approaches in pediatric liver transplant may be of benefit in the prevention of HAT. A prospective multi‐institutional study of regimen—possibly including aspirin—following transplantation could have significant value.
- 5 March 2023
- Published by Wiley in Journal of Parenteral and Enteral Nutrition
- Vol. 47 (4) , 501-510
Association between congenital heart disease and parenteral nutrition–associated liver disease in neonates: A retrospective cohort study
Objective: Infants receiving parenteral nutrition (PN) are at increased risk of PN‐associated liver disease (PNALD), which can lead to hepatic fibrosis. Congenital heart disease (CHD) represents a risk factor for hepatic fibrosis, so this study sought to better understand whether infants with CHD were at elevated risk of PNALD when receiving long‐term PN.Study Design: This study includes a retrospective cohort of infants at a level IV neonatal intensive care unit from 2010 to 2020 who received long‐term PN during the first 8 weeks of life. A time‐varying Cox survival model was used to model risk of PNALD between infants with and without CHD, adjusted for demographics, surgical intervention, and PN exposure, using a 5000‐iteration bootstrap estimation. Secondary analyses evaluated risk against discrete CHD diagnoses, and sensitivity analysis was performed on the magnitude and quantity of direct bilirubin laboratory measurements making up the PNALD definition.Results: Neonates with CHD were found to be at higher risk for PNALD during or soon after long‐term PN exposure. A pattern of increasing association strength with increasing bilirubin threshold suggests infants with CHD may also experience higher degrees of injury.Conclusions: This work offers a step in understanding how diagnoses can be factored into neonate PN prescription. Future work will explore modifications in lipid profiles and timing to mitigate risk in patients with CHD.
- 5 March 2023
- Published by Wiley in Journal of Parenteral and Enteral Nutrition
- Vol. 47 (4) , 501-510
Association between congenital heart disease and parenteral nutrition–associated liver disease in neonates: A retrospective cohort study
Objective: Infants receiving parenteral nutrition (PN) are at increased risk of PN‐associated liver disease (PNALD), which can lead to hepatic fibrosis. Congenital heart disease (CHD) represents a risk factor for hepatic fibrosis, so this study sought to better understand whether infants with CHD were at elevated risk of PNALD when receiving long‐term PN.Study Design: This study includes a retrospective cohort of infants at a level IV neonatal intensive care unit from 2010 to 2020 who received long‐term PN during the first 8 weeks of life. A time‐varying Cox survival model was used to model risk of PNALD between infants with and without CHD, adjusted for demographics, surgical intervention, and PN exposure, using a 5000‐iteration bootstrap estimation. Secondary analyses evaluated risk against discrete CHD diagnoses, and sensitivity analysis was performed on the magnitude and quantity of direct bilirubin laboratory measurements making up the PNALD definition.Results: Neonates with CHD were found to be at higher risk for PNALD during or soon after long‐term PN exposure. A pattern of increasing association strength with increasing bilirubin threshold suggests infants with CHD may also experience higher degrees of injury.Conclusions: This work offers a step in understanding how diagnoses can be factored into neonate PN prescription. Future work will explore modifications in lipid profiles and timing to mitigate risk in patients with CHD.
- Open Access
- 13 October 2022
- Published by Wolters Kluwer Health in Hepatology
- Vol. 77 (2) , 512-529
Natural history of liver disease in a large international cohort of children with Alagille syndrome: Results from the GALA study
Background and Aims: Alagille syndrome (ALGS) is a multisystem disorder, characterized by cholestasis. Existing outcome data are largely derived from tertiary centers, and real‐world data are lacking. This study aimed to elucidate the natural history of liver disease in a contemporary, international cohort of children with ALGS. Approach and Results: This was a multicenter retrospective study of children with a clinically and/or genetically confirmed ALGS diagnosis, born between January 1997 and August 2019. Native liver survival (NLS) and event‐free survival rates were assessed. Cox models were constructed to identify early biochemical predictors of clinically evident portal hypertension (CEPH) and NLS. In total, 1433 children (57% male) from 67 centers in 29 countries were included. The 10 and 18‐year NLS rates were 54.4% and 40.3%. By 10 and 18 years, 51.5% and 66.0% of children with ALGS experienced ≥1 adverse liver‐related event (CEPH, transplant, or death). Children (>6 and ≤12 months) with median total bilirubin (TB) levels between ≥5.0 and p < 0.001). Conclusions: In this large international cohort of ALGS, only 40.3% of children reach adulthood with their native liver. A TB <5.0 mg/dl between 6 and 12 months of age is associated with better hepatic outcomes. These thresholds provide clinicians with an objective tool to assist with clinical decision‐making and in the evaluation of therapies.
- 13 October 2022
- Published by Wolters Kluwer Health in Hepatology
- Vol. 77 (2) , 512-529
Open AccessNatural history of liver disease in a large international cohort of children with Alagille syndrome: Results from the GALA study
Background and Aims: Alagille syndrome (ALGS) is a multisystem disorder, characterized by cholestasis. Existing outcome data are largely derived from tertiary centers, and real‐world data are lacking. This study aimed to elucidate the natural history of liver disease in a contemporary, international cohort of children with ALGS. Approach and Results: This was a multicenter retrospective study of children with a clinically and/or genetically confirmed ALGS diagnosis, born between January 1997 and August 2019. Native liver survival (NLS) and event‐free survival rates were assessed. Cox models were constructed to identify early biochemical predictors of clinically evident portal hypertension (CEPH) and NLS. In total, 1433 children (57% male) from 67 centers in 29 countries were included. The 10 and 18‐year NLS rates were 54.4% and 40.3%. By 10 and 18 years, 51.5% and 66.0% of children with ALGS experienced ≥1 adverse liver‐related event (CEPH, transplant, or death). Children (>6 and ≤12 months) with median total bilirubin (TB) levels between ≥5.0 and p < 0.001). Conclusions: In this large international cohort of ALGS, only 40.3% of children reach adulthood with their native liver. A TB <5.0 mg/dl between 6 and 12 months of age is associated with better hepatic outcomes. These thresholds provide clinicians with an objective tool to assist with clinical decision‐making and in the evaluation of therapies.
- Open Access
- 9 July 2022
- Published by Wiley in Clinical and Translational Science
- Vol. 15 (9) , 2241-2250
The effect of neuropsychiatric medication on pediatric nonalcoholic fatty liver disease
Obese and overweight children are at risk of developing nonalcoholic fatty liver disease (NAFLD), which can lead to steatohepatitis, cirrhosis, and liver transplantation. Neuropsychiatric conditions affect an increasing proportion of children and often require neuropsychiatric medications (NPMs) that are associated with weight gain and/or drug‐induced liver injury. We sought to evaluate the role that the extended use of NPMs play in pediatric NAFLD. Medical chart review was conducted for 260 patients with NAFLD (NPM = 77, non‐NPM = 183) seen in the Liver Care Center at Children’s Mercy Hospital between 2000 and 2016. Outcome measures included body mass index (BMI) percentile, BMI z‐score, aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, and gamma glutamyltransferase, and were collected at diagnosis, 6–18 month follow‐up, and 18–36 months. Controlling for race and metformin, there was a significant increase over time in BMI z‐score (p < 0.01) and total bilirubin (p = 0.03), with only initial decreases in ALT (p < 0.01) and AST (p < 0.01). Except for higher total bilirubin in the non‐NPM group, no main effect of group or interaction effect was found. Similar patterns remained when subjects were analyzed by NPM drug class. Further study is needed to confirm these findings and to evaluate the effects of NPM dose and duration of exposure, by drug class, on pediatric NAFLD outcomes.
- 9 July 2022
- Published by Wiley in Clinical and Translational Science
- Vol. 15 (9) , 2241-2250
Open AccessThe effect of neuropsychiatric medication on pediatric nonalcoholic fatty liver disease
Obese and overweight children are at risk of developing nonalcoholic fatty liver disease (NAFLD), which can lead to steatohepatitis, cirrhosis, and liver transplantation. Neuropsychiatric conditions affect an increasing proportion of children and often require neuropsychiatric medications (NPMs) that are associated with weight gain and/or drug‐induced liver injury. We sought to evaluate the role that the extended use of NPMs play in pediatric NAFLD. Medical chart review was conducted for 260 patients with NAFLD (NPM = 77, non‐NPM = 183) seen in the Liver Care Center at Children’s Mercy Hospital between 2000 and 2016. Outcome measures included body mass index (BMI) percentile, BMI z‐score, aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, and gamma glutamyltransferase, and were collected at diagnosis, 6–18 month follow‐up, and 18–36 months. Controlling for race and metformin, there was a significant increase over time in BMI z‐score (p < 0.01) and total bilirubin (p = 0.03), with only initial decreases in ALT (p < 0.01) and AST (p < 0.01). Except for higher total bilirubin in the non‐NPM group, no main effect of group or interaction effect was found. Similar patterns remained when subjects were analyzed by NPM drug class. Further study is needed to confirm these findings and to evaluate the effects of NPM dose and duration of exposure, by drug class, on pediatric NAFLD outcomes.